BB Biotech AG (BBZA.DE)
EUR 39.05
(0.77%)
EUR 39.05
(0.77%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 304.9 Million CHF | -16.98% |
| 2022 | 367.25 Million CHF | 3.45% |
| 2021 | 355 Million CHF | 463.49% |
| 2020 | 63 Million CHF | -61.01% |
| 2019 | 161.59 Million CHF | -20.13% |
| 2018 | 202.33 Million CHF | 104.12% |
| 2017 | 99.12 Million CHF | -55.59% |
| 2016 | 223.21 Million CHF | 34.87% |
| 2015 | 165.5 Million CHF | 311.02% |
| 2014 | 40.26 Million CHF | -56.23% |
| 2013 | 92 Million CHF | -34.26% |
| 2012 | 139.94 Million CHF | -6.63% |
| 2011 | 149.88 Million CHF | 5.44% |
| 2010 | 142.14 Million CHF | 2972.83% |
| 2009 | 4.62 Million CHF | -95.96% |
| 2008 | 114.36 Million CHF | -63.09% |
| 2007 | 309.82 Million CHF | 2.98% |
| 2006 | 300.85 Million CHF | 37.79% |
| 2005 | 218.35 Million CHF | 5987.26% |
| 2004 | 3.58 Million CHF | -91.76% |
| 2003 | 43.51 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 322.48 Million CHF | -8.9% |
| 2024 Q1 | 353.99 Million CHF | 16.1% |
| 2023 Q3 | 302.1 Million CHF | -2.07% |
| 2023 Q4 | 304.9 Million CHF | 0.93% |
| 2023 FY | 304.9 Million CHF | -16.98% |
| 2023 Q2 | 308.5 Million CHF | -2.22% |
| 2023 Q1 | 315.5 Million CHF | -13.09% |
| 2022 Q1 | 359.63 Million CHF | -0.26% |
| 2022 Q2 | 334.46 Million CHF | -7.0% |
| 2022 Q3 | 306.88 Million CHF | -8.25% |
| 2022 Q4 | 363 Million CHF | 18.29% |
| 2022 FY | 367.25 Million CHF | 3.45% |
| 2021 Q2 | 310.07 Million CHF | -14.92% |
| 2021 Q4 | 360.58 Million CHF | 37.76% |
| 2021 Q3 | 261.75 Million CHF | -15.58% |
| 2021 Q1 | 364.46 Million CHF | 382.17% |
| 2021 FY | 355 Million CHF | 463.49% |
| 2020 Q2 | 204.46 Million CHF | -40.07% |
| 2020 Q1 | 341.16 Million CHF | 111.12% |
| 2020 Q3 | 249.43 Million CHF | 22.0% |
| 2020 Q4 | 75.58 Million CHF | -69.7% |
| 2020 FY | 63 Million CHF | -61.01% |
| 2019 Q2 | 375.12 Million CHF | -1.83% |
| 2019 Q1 | 382.13 Million CHF | 88.87% |
| 2019 FY | 161.59 Million CHF | -20.13% |
| 2019 Q4 | 161.59 Million CHF | 0.0% |
| 2018 Q3 | 332.31 Million CHF | -9.14% |
| 2018 FY | 202.33 Million CHF | 104.12% |
| 2018 Q2 | 365.73 Million CHF | 19.9% |
| 2018 Q1 | 305.02 Million CHF | 207.72% |
| 2018 Q4 | 202.33 Million CHF | -39.12% |
| 2017 Q2 | 30.12 Million CHF | -90.4% |
| 2017 Q1 | 313.66 Million CHF | 40.52% |
| 2017 FY | 99.12 Million CHF | -55.59% |
| 2017 Q4 | 99.12 Million CHF | 416.06% |
| 2017 Q3 | 19.2 Million CHF | -36.23% |
| 2016 FY | 223.21 Million CHF | 34.87% |
| 2016 Q3 | 243.22 Million CHF | -31.78% |
| 2016 Q1 | 354.48 Million CHF | 114.18% |
| 2016 Q2 | 356.54 Million CHF | 0.58% |
| 2016 Q4 | 223.21 Million CHF | -8.22% |
| 2015 Q3 | 94.13 Million CHF | 183.96% |
| 2015 Q4 | 165.5 Million CHF | 75.82% |
| 2015 FY | 165.5 Million CHF | 311.02% |
| 2015 Q1 | 42.2 Million CHF | 4.82% |
| 2015 Q2 | 33.15 Million CHF | -21.45% |
| 2014 Q3 | 159.42 Million CHF | -14.42% |
| 2014 FY | 40.26 Million CHF | -56.23% |
| 2014 Q4 | 40.26 Million CHF | -74.74% |
| 2014 Q2 | 186.28 Million CHF | 2.11% |
| 2014 Q1 | 182.43 Million CHF | 98.3% |
| 2013 Q4 | 92 Million CHF | -38.42% |
| 2013 FY | 92 Million CHF | -34.26% |
| 2013 Q1 | 140.8 Million CHF | 0.62% |
| 2013 Q3 | 149.38 Million CHF | 44.2% |
| 2013 Q2 | 103.59 Million CHF | -26.43% |
| 2012 Q4 | 139.94 Million CHF | -14.71% |
| 2012 FY | 139.94 Million CHF | -6.63% |
| 2012 Q1 | 117.37 Million CHF | -21.69% |
| 2012 Q2 | 163.78 Million CHF | 39.54% |
| 2012 Q3 | 164.08 Million CHF | 0.18% |
| 2011 FY | 149.88 Million CHF | 5.44% |
| 2011 Q2 | 184.67 Million CHF | 10.11% |
| 2011 Q3 | 125.75 Million CHF | -31.91% |
| 2011 Q4 | 149.88 Million CHF | 19.19% |
| 2011 Q1 | 167.71 Million CHF | 17.98% |
| 2010 FY | 142.14 Million CHF | 2972.83% |
| 2010 Q2 | 189.19 Million CHF | 179.78% |
| 2010 Q1 | 67.62 Million CHF | 1361.8% |
| 2010 Q4 | 142.14 Million CHF | -0.6% |
| 2010 Q3 | 143 Million CHF | -24.41% |
| 2009 FY | 4.62 Million CHF | -95.96% |
| 2009 Q4 | 4.62 Million CHF | 0.0% |
| 2008 FY | 114.36 Million CHF | -63.09% |
| 2007 FY | 309.82 Million CHF | 2.98% |
| 2006 FY | 300.85 Million CHF | 37.79% |
| 2005 FY | 218.35 Million CHF | 5987.26% |
| 2004 FY | 3.58 Million CHF | -91.76% |
| 2003 FY | 43.51 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| BioNTech SE | 2.76 Billion EUR | 88.954% |
| CureVac N.V. | 271.53 Million EUR | -12.289% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 67.749% |
| Biotest Aktiengesellschaft | 945.4 Million EUR | 67.749% |
| BRAIN Biotech AG | 47.92 Million EUR | -536.229% |
| Formycon AG | 387.61 Million EUR | 21.339% |
| Heidelberg Pharma AG | 21.01 Million EUR | -1350.99% |
| Medigene AG | 10.65 Million EUR | -2762.911% |